Current therapies for Parkinson's disease(PD)are palliative,of which the levodopa/carbidopa therapy remains the primary choice but is unable to modulate the progression of neurodegeneration.Due to the complication...Current therapies for Parkinson's disease(PD)are palliative,of which the levodopa/carbidopa therapy remains the primary choice but is unable to modulate the progression of neurodegeneration.Due to the complication of such a multifactorial disorder and significant limitations of the therapy,numerous genetic approaches have been proved effective in finding out genes and mechanisms implicated in this disease.Following the observation of a higher frequency of PD in Gaucher's disease(GD),a lysosomal storage condition,mutations of glycosylceramidase beta(GBA)encoding glucocerebrosidase(GCase)have been shown to be involved and have been explored in the context of PD.GBA mutations are the most common genetic risk factor of PD.Various studies have revealed the relationships between PD and GM gene mutations,facilitating a better understanding of this disorder.Various hypotheses delineate that the pathological mutations of GBA minimize the enzymatic activity of GCase,which affects the proliferation and clearance of α-synuclein;this affects the lysosomal homeostasis,exacerbating the endoplasmic reticulum stress or encouraging the mitochondrial dysfunction.Identification of the pathological mechanisms underlying the GM-associated parkinsonism(GBA+PD)advances our understanding of PD.This review based on current literature aims to elucidate various genetic and clinical characteristics correlated with GBA mutations and to identify the numerous pathological processes underlying GBA+PD.We also delineate the therapeutic strategies to interfere with the mutant GCase function for further improvement of the related asynuclein-GCase crosstalks.Moreover,the various therapeutic approaches such as gene therapy,chaperone proteins,and histone deacetylase inhibitors for the treatment of GBA+PD are discussed.展开更多
文摘Current therapies for Parkinson's disease(PD)are palliative,of which the levodopa/carbidopa therapy remains the primary choice but is unable to modulate the progression of neurodegeneration.Due to the complication of such a multifactorial disorder and significant limitations of the therapy,numerous genetic approaches have been proved effective in finding out genes and mechanisms implicated in this disease.Following the observation of a higher frequency of PD in Gaucher's disease(GD),a lysosomal storage condition,mutations of glycosylceramidase beta(GBA)encoding glucocerebrosidase(GCase)have been shown to be involved and have been explored in the context of PD.GBA mutations are the most common genetic risk factor of PD.Various studies have revealed the relationships between PD and GM gene mutations,facilitating a better understanding of this disorder.Various hypotheses delineate that the pathological mutations of GBA minimize the enzymatic activity of GCase,which affects the proliferation and clearance of α-synuclein;this affects the lysosomal homeostasis,exacerbating the endoplasmic reticulum stress or encouraging the mitochondrial dysfunction.Identification of the pathological mechanisms underlying the GM-associated parkinsonism(GBA+PD)advances our understanding of PD.This review based on current literature aims to elucidate various genetic and clinical characteristics correlated with GBA mutations and to identify the numerous pathological processes underlying GBA+PD.We also delineate the therapeutic strategies to interfere with the mutant GCase function for further improvement of the related asynuclein-GCase crosstalks.Moreover,the various therapeutic approaches such as gene therapy,chaperone proteins,and histone deacetylase inhibitors for the treatment of GBA+PD are discussed.
